IR_propancbiopharma
Nov 19, 1:48 PM
From preclinical research to clinical development preparations, several milestones have helped shape
$PPCB's path forward in 2026.
· Q1: Preclinical findings, research collaborations, and bioanalytical development.
· Q2: GMP manufacturing preparations to support clinical development.
· Q3: Clinical protocol development, site feasibility assessments, and a clearer Phase 1b roadmap.
· Q4: Additional preclinical findings, analytical progress, and preparations for regulatory and ethics submissions.
What's next?
Propanc is targeting a Phase 1b first-in-human study involving up to 50 patients with advanced solid tumors, with initial patient screening planned for February 2027.
The next milestone is translating these preparations into clinical execution.
0 replies